Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nokian Tyres OYJ Unsponsored Finland ADR NKRKY

Nokian Tyres plc is a Finland-based company active in the tire manufacturing industry. The Company diversifies its activities into three main business segments: Passenger Car Tires, Heavy Tires and Vianor. The Passenger Car Tires business segment comprises the development and production of summer and winter tires for cars and vans. The Heavy Tires business segment comprises tires for forestry machinery, special tires and agricultural machinery, tractors and industrial machinery. The Vianor business segment is specialized in car maintenance and tyre services. The tyre products cover all sorts of tyres for passenger cars, vans and trucks, as well as heavy specialist machinery. In addition to Nokian Tyres’ products, Vianor also represents and sells other tyre brands. The Company diversifies its activities into geographical segments: Finland, Sweden, Norway, Other Europe and North America.


PINL:NKRKY - Post by User

Post by CoressPringson Apr 15, 2022 8:51am
44 Views
Post# 34606187

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS Video


FSD Pharma is delighted to announce pre-clinical findings indicating the efficacy of Lucid-MS, its flagship medication candidate, in treating Multiple Sclerosis. Lucid-MS's therapeutic potential is an industry first, and we'd like to provide visual evidence of functional recovery in pre-clinical individuals in this video!

<< Previous
Bullboard Posts
Next >>